The sixth Forum, again on ALK inhibitors, concluded that there were more clinical trials and regulatory submissions since the first Forum, ALK inhibitors should be included in front-line therapy of anaplastic large cell lymphoma (ALCL), the efficacy and safety of lorlatinib needed to be determined in front-line therapy in patients with neuroblastoma, and ALK inhibitors with very good central nervous system (CNS) penetration should be evaluated in CNS tumors with ALK fusions (13). This evidence concerns the gene ALK and neuroblastoma.